TRCT
OBIO icon

Tower Research Capital (TRC)’s Orchestra BioMed OBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5K Buy
3,601
+3,054
+558% +$12.5K ﹤0.01% 3761
2026
Q1 		$2.33K Sell
547
-99
-15% -$421 ﹤0.01% 4496
2025
Q4 		$2.68K Buy
+646
New +$2.61K ﹤0.01% 4484
2025
Q3 		– Sell
-27,922
Closed -$74.8K – 5494
2025
Q2 		$74.8K Buy
27,922
+25,666
+1,138% +$74.9K ﹤0.01% 2622
2025
Q1 		$9.66K Sell
2,256
-67
-3% -$333 ﹤0.01% 3747
2024
Q4 		$9.29K Buy
2,323
+407
+21% +$2.19K ﹤0.01% 3917
2024
Q3 		$9.85K Sell
1,916
-2,969
-61% -$19.4K ﹤0.01% 3828
2024
Q2 		$39.8K Buy
4,885
+3,174
+186% +$18.4K ﹤0.01% 3270
2024
Q1 		$9.02K Sell
1,711
-757
-31% -$5.13K ﹤0.01% 3915
2023
Q4 		$22.5K Buy
2,468
+911
+59% +$6.22K ﹤0.01% 3576
2023
Q3 		$13.6K Buy
1,557
+1,012
+186% +$6.8K ﹤0.01% 3772
2023
Q2 		$3.81K Sell
545
-363
-40% -$5.51K ﹤0.01% 5020
2023
Q1 		$18K Sell
908
-1,215
-57% -$14.1K ﹤0.01% 3568
2022
Q4 		$21K Hold
2,123
– – ﹤0.01% 3096
2022
Q3 		$21K Buy
2,123
+984
+86% +$9.76K ﹤0.01% 3898
2022
Q2 		$11K Buy
1,139
+54
+5% +$537 ﹤0.01% 4383
2022
Q1 		$11K Buy
1,085
+888
+451% +$8.77K ﹤0.01% 4194
2021
Q4 		$2K Buy
197
+50
+34% +$493 ﹤0.01% 5644
2021
Q3 		$1K Sell
147
-545
-79% -$5.38K ﹤0.01% 5510
2021
Q2 		$7K Buy
692
+147
+27% +$1.52K ﹤0.01% 4562
2021
Q1 		$6K Buy
+545
New +$6.64K ﹤0.01% 4600

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Tower Research Capital (TRC)'s OBIO Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Orchestra BioMed (OBIO) stake by 558% in Q2 2026, buying an estimated $12.5K and bringing the position to 3,601 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3761.

Tower Research Capital (TRC) first reported a position in OBIO in Q1 2021 and has held it in 21 quarters since. The position peaked at $74.8K in Q2 2025. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Tower Research Capital (TRC) held 3,601 shares of Orchestra BioMed worth $15.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,054 Orchestra BioMed shares in Q2 2026, an estimated $12.5K.
  • Orchestra BioMed made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3761 holding.
  • Tower Research Capital (TRC) first reported a position in Orchestra BioMed in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Orchestra BioMed position peaked at $74.8K in Q2 2025.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.